Covx Technologies Ireland Limited

Pfizer Corporation

Nancy Jane Levin

Moorthy Sitharamaiah Suriyanarayana Palanki

Mark John Pozzo

Palani Balu

Tetsuya Ishino

Rory Francis Finn

Olivier Alexandre Laurent

Jin Xie

Haim Moskowitz

Jie Huang

Erin Kristen Parsons

Tapan Kanti Das

Gopinath Vedachalam Annathur

Nicholas Gary Luksha

Joseph Patrick Martin, Jr

Gregory Allan Waszak

Tamara Shafer Hodge

Bernard Norman Violand

The present invention provides a composition of the formula: [FGF21-1Linker]-[Ab]-[2-Linker-Ex4]; wherein FGF21 is an FGF21 homologue; and Ex4 is an Exendin4 homologue; and Ab is an aldolase catalytic antibody or antigen binding portion thereof; and the 1linker is covalently attached to the side chain of a protein-linking residue in FGF21 and to a combining site of the antibody, and the 2linker is covalently attached to the side chain of a peptide-linking residue in Ex4 and to a combining site of the antibody, and wherein the first and second linker are the same or different. Various uses of the compounds are provided, including methods to prevent or treat diabetes or diabetes-related conditions.

Anti-diabetic compounds

The present invention provides a FGF21 molecule covalently attached to the combining site of an antibody via a linker, wherein the linker is covalently attached to the side chain of a linking residue within FGF21. Various uses of the compounds are provided, including methods to prevent or treat diabetes or diabetes-related conditions.

FGF21 conjugates and anti-diabetic uses thereof

Growing community of inventors

Encinitas, CA, United States of America

Nancy Jane Levin